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Abstract
Background: Judgments underlying guideline recommendations are seldom recorded and presented in a
systematic fashion. The GRADE Evidence-to-Decision Framework (EtD) offers a transparent way to record and report
guideline developers’ judgments. In this paper, we report the experiences with the EtD frameworks in 15 real
guideline panels.
Methods: Following the guideline panel meetings, we asked methodologists participating in the panel to provide
feedback regarding the EtD framework. They were instructed to consider their own experience and the feedback
collected from the rest of the panel. Two investigators independently summarized the responses and jointly
interpreted the data using pre-specified domains as coding system. We asked methodologists to review the results
and provide further input to improve the structure of the EtDs iteratively.
Results: The EtD framework was well received, and the comments were generally positive. Methodologists felt that
in a real guideline panel, the EtD framework helps structuring a complex process through relatively simple steps in
an explicit and transparent way. However, some sections (e.g., “values and preferences” and “balance between
benefits and harms”) required further development and clarification that were considered in the current version of
the EtD framework.
Conclusions: The use of an EtD framework in guideline development offers a structured and explicit way to record
and report the judgments and discussion of guideline panels during the formulation of recommendations. In
addition, it facilitates the formulation of recommendations, assessment of their strength, and identifying gaps in
research.
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Background
Clinical practice guidelines are an efficient way to bridge
the gap between research evidence, expert experience, and
decision-making [1–4]. In order to be trustworthy, guide-
lines need to be explicit regarding the methods used to
summarize the evidence and rate its certainty (also known
as quality of the evidence or confidence in the effect esti-
mates) and about the judgments involved in moving from
evidence to recommendations [5–7]. Unfortunately,
such judgments are rarely recorded and presented in a
systematic way.
The Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) working group (www.gra
deworkinggroup.org), a collaborative of over 500 scientists,
clinicians, and people with other backgrounds, has devel-
oped an approach to assessing the certainty in the body of
evidence summarized in systematic reviews that support a
decision or guideline recommendation, called the GRADE
approach [8, 9]. This approach is used by over 90 organi-
zations, including the World Health Organization, the
National Institutes of Health and Care Excellence, the
Canadian Task Force for the Preventive Services, numerous
professional organizations, and the Cochrane Collaboration.
There are over 20,000 citations to GRADE’s methodo-
logical work, and thousands of recommendations have
been developed following the GRADE approach. GRADE
can be used to evaluate different types of evidence, includ-
ing evidence for intervention effects (including multiple
treatment comparisons), test accuracy, prognosis, and
resources.
In the context of its “Developing and Evaluating Com-
munication Strategies to Support Informed Decisions and
Practice Based on Evidence (DECIDE)” project, GRADE
has developed strategies for the targeted communication
of evidence-based recommendations to different stake-
holders [10]. One of such strategies is the GRADE Evi-
dence to Decision (EtD) Framework, meant to structure
development of both recommendations (e.g., clinical rec-
ommendations) and decisions (e.g., coverage or public
health decisions) using the GRADE approach. Each EtD
framework includes detailed sections describing (a) the
question and background, (b) an assessment of the evi-
dence, and (c) the conclusions. A summary of the effects
of alternative management strategies on patient-important
outcomes, data about patients’ values and preferences,
and information about resource utilization are part of the
assessment section [11–13]. The EtD framework also fea-
tures information regarding acceptability and feasibility of
the alternative management strategies, as well their impact
on health equity. This data are obtained from current sys-
tematic reviews when available or, more often, updating of
previous reviews or the de novo systematic reviews. Fi-
nally, The EtD framework provides an explicit record of
the judgments made by guideline panelists that ultimately
determine the direction and strength of recommendations
or decisions. In this paper, we report on the first experi-
ence with the EtD framework for clinical recommenda-
tions in real guideline panels.
Methods
The EtD frameworks
The EtD frameworks evaluated in this study included
different versions at various stages of its full develop-
ment during the DECIDE project. The earliest version of
the full GRADE EtD framework was used in 2012 in
World Health Organization (WHO) Guidelines for the
treatment of multidrug-resistant tuberculosis [14]. The
last version of the EtD applied in this study was used in
a series of guidelines for the Ministry of Health in Saudi
Arabia in 2014 (http://www.moh.gov.sa/depts/Proofs/
Pages/Guidelines.aspx). The EtDs were developed based
on GRADE evidence to decision tables first utilized in a
WHO guideline on avian influenza [15, 16]. The original
evidence to decision table (rather than framework) only
included five decision criteria [16, 17]. Table 1 describes
the iterative changes that were made to the EtD frame-
work during this project. Additional file 1: Table S1 of-
fers an example of the later EtD frameworks tested in
this study with 11 criteria and the question and conclu-
sion section [18]. Four panels utilized on-line versions of
the interactive EtD frameworks through GRADE’s soft-
ware GRADEpro [19] while the other panels used paper-
based versions (Table 2). All EtDs were transferred for
final agreement with panel members and publication of
the guideline to GRADEpro.
We will describe its main features of the EtD here
(Additional file 1: Table S1). The header of the table
Table 1 Evolution of the EtD framework
Earlier version Latest version
Used on the World Health
Organization and Spanish
Guidelines program
Used in Kingdom of Saudi Arabia, World
Allergy Organization, Colombian
guideline program and rare diseases
guidelines
Did not include “prioritization
of the problem”
Included a question evaluating the
priority of the problem
Included a single question
evaluating the balance between
health benefits and harms of
the intervention of interest
The original question was disaggregated
into 3 questions: (1) the magnitude of
the health benefits, (2) the magnitude of
the health harms, and (3) the balance
between health benefits and harms.
Included a single question
evaluating the variability of
patients’ values and preferences
A judgment regarding the uncertainty
about patients’ values and preferences
was added.
Included a single question
evaluating the cost of the
intervention in relation to
the benefits
The original question was disaggregated
into 2 questions: (1) what is the cost of
the intervention and (2) how large is this
cost in relation to the benefits.
Included equity as an additional
criterion
Acceptability and feasibility were
added to equity
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provides details about the clinical question, clearly out-
lining its components following the PICO framework
and any relevant background information. The first col-
umn offers the factors or criteria being evaluated framed
as questions (e.g., is the problem a priority?). The second
column identifies the required judgments by panels and
allows recording of these judgments for each criterion.
The relevant research evidence and additional consider-
ations upon which the judgments are based redocumen-
ted in third column and fourth column, respectively.
While the research evidence should be based on systematic
reviews of the literature, additional considerations allow
capturing specific considerations and information about the
local context in which the recommendation will be applied.
Finally, the framework captures the judgments leading to
the direction and strength of the recommendation or deci-
sion. In addition, there is free space to include subgroup
and implementation considerations, as well as information
regarding futures updates, monitoring, and research prior-
ities. In the four guidelines that used GRADEpro, GRADE’s
online tool to assess evidence and develop recommenda-
tions, the information was shown on a large screen during
the panel meeting and judgments and additional con-
siderations were added online to the EtD during the panel
meetings [19]. The version of the EtD in GRADEpro corre-
sponded to the stage of the EtD development (shown in
Additional file 1: Table S1) while the current version of
GRADEpro that is available on the web (www.gradepro.org)
includes the fully developed static and interactive EtD.
Sample
We used the EtD frameworks in 15 international guideline
panels (Table 2). Two guideline panels were organized by
international agencies (World Health Organization and
World Allergy Organization); 12 panels were in the con-
text of national guideline programs (10 in the Kingdom of
Saudi Arabia, 1 in Colombia, and 1 in Spain); and 1 panel
was part of an effort to produce establish methods for de-
veloping guidance on rare diseases (Italy and Germany).
Data collection
All guidelines were developed between 2012 and 2014.
The guidelines for Saudi Arabia were produced by ten
panels, five of them meeting in parallel followed by con-
secutive meetings of the other five panels. While the
preparatory work for these panels was extensive and pre-
ceded the panel meetings, the panel meetings lasted
2 days each [20]. Two or three methodologists super-
vised two panels each sequentially over a total of 4 days.
The other guideline panels met over 1 or 2 days and
were also led by pairs of methodologists. Following the
guideline panel meetings, we asked the methodologists
leading the panel to provide feedback regarding the EtD
framework. Specifically, three investigators (WW, PAC,
HJS) developed a spreadsheet with pre-specified do-
mains and we asked the methodologists to provide free
text comments on each domain and also free text com-
ments about their overall experience with the framework
(Additional file 2). Two of the three investigators (WW
and HJS) who developed the data collection sheet also
participated as methodologists in guideline panels and
therefore provided comments and feedback to the EtD
framework. We choose this method for collecting the
data given its relatively quick implementation just after
the panel meetings. We instructed the methodologists to
Table 2 Guideline panels on which the GRADE Evidence to
Decision (EtD) Framework was tested
Guideline panels
Kingdom of Saudi Arabia Guideline Programa
1. Management of allergic rhinitis in adults and children
2. Antithrombotic Treatment of Patients with Non-valvular Atrial Fibrillation
3. Use of Screening Strategies for Detection of Breast Cancer
(used interactive EtD in GRADEpro during panel meeting)
4. Screening and Treatment of Precancerous Lesions for Cervical
Cancer Prevention
5. Diagnosis of Suspected First Deep Vein Thrombosis of Lower Extremity
6. Timing of Initiation of Dialysis
7. Role of Vitamin D, Calcium and Exercise in Fracture Prevention in Elderly
8. Use of Thrombolytic Therapy in Acute Stroke
9. Prevention of Venous Thromboembolism in Stroke
10. Treatment of Venous Thromboembolism
World Health Organization Guideline Programb
11. The use of bedaquiline in the treatment of multidrug resistant
tuberculosis (used interactive EtD in GRADEpro during panel meeting)
WAO Guideline Programc
12. Guidelines for allergic diseases prevention (GLAD-P) (used interactive
EtD in GRADEpro during panel meeting)
Colombian Guidelines programd
13. Clinical practice guidelines for evidence-based care of HIV infection
in children
Spanish Guidelines programe
14. Spanish Guidelines program: Childhood asthma
Rare diseasef







eGrupo de trabajo de la Guía de Práctica Clínica sobre asma infantil. Guía de
Práctica Clínica sobre asma infantil. Plan de Calidad para el Sistema Nacional
de Salud del Ministerio de Sanidad y Política Social. Osteba; 2014. Guías de
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consider their own experience with the EtD framework
and also the feedback collected from the rest of the pan-
elists during the guideline panel meeting. After a first
round of feedback, we provided a summary of the results
to the methodologists for further input.
Data analysis
Two investigators (IN and RBP) independently identified
themes from the feedback obtained from the methodolo-
gists. They used the pre-specified domains as coding sys-
tem. Then, the two investigators jointly interpreted the
data and organized the themes into the following cat-
egories: general comments about the framework and
comments about specific sections within the framework.
All participants were invited to review and comment on
a draft report of the results.
Results
Context and methodologists
The topics covered by guideline panels were diverse, in-
cluding cardiovascular diseases (5 guidelines), asthma
and allergy (3 guidelines), infectious diseases (2 guide-
lines), cancer screening and diagnosis (2 guidelines), and
others (3 guidelines). Most of the guidelines were fo-
cused on adults (11 guidelines) (Table 2).
Ten methodologists led the guideline development on
the 15 panels, and for all guidelines, a second method-
ologist provided backup support. Seven of the panel
leads were physicians, two dentists, and one registered
nurse, all of them with postgraduate training in health
research methods or a related discipline. All guideline
methodologists had formal training and experience in
conducting systematic reviews and in using the GRADE
approach to formulate recommendations. They were all
members of the GRADE working group. For 13 out of
the 15 guidelines, one highly experienced guideline
methodologist led the panel discussions supported by
another guideline methodologist. Most of the highly ex-
perienced methodologists had led multiple systematic
reviews and high level guideline panels at major inter-
national organizations (e.g., WHO) or professional soci-
eties with large guideline programs (e.g., American
Thoracic Society or American College of Chest Physi-
cians). The gender distribution was six males and four
females, and the mean age was 37.8 years (standard devi-
ation 6.3). All of them provided feedback about the EtD
framework.
General comments about the EtD framework
Table 3 summarizes the results by themes. In general,
the EtD framework was well received and the comments
were mostly positive. The methodologists felt that in a
real guideline panel, the EtD framework helps structur-
ing a complex group process through relatively simple
steps in an explicit and transparent way. Further, two
methodologists commented that the explicitness of the
framework could help having an accurate idea of the
underlying evidence and protecting against inappropriate
recommendations.
Two methodologists stated that the wording of the
questions and options to answer were suboptimal for
recommendations comparing two active interventions
(instead of one active intervention against placebo/no
treatment). Also, three methodologists raised concerns
regarding the length of the framework and the relevance
of some sections in specific circumstances. In particular,
considerations regarding feasibility, accessibility, and
equity were considered less relevant in the context of
clinical recommendations. Finally, two methodologists
stated that in order to take full advantage of the ETD
framework, it is necessary to be familiar with the
GRADE approach and with the framework itself. There-
fore, for new users, previous training may be helpful for
successful implementation and use. For example, one
methodologist stated, “Until you see the process you
don’t appreciate all the real work and value of the forms
and filling out information before the panel meeting, etc.
You must go through the process and use the [EtD] and
see the outcome.”
Comments about specific sections
The sections “values and preferences” and “balance of
benefits and harms” posed difficulties in several panels.
Regarding the “values and preferences” section, the
GRADE approach requires guideline panelists to judge
whether there is important variability in how patients’
value the main outcomes and to what extent there is im-
portant uncertainty about this. In case of any of the two,
panels should consider issuing a weak recommendation.
The main concern with this question was that the an-
swer options did not differentiate between the variability
and uncertainty in patients’ values and preferences, cre-
ating some confusion among panelists. Four methodolo-
gists suggested dividing this question in two.
Regarding the balance between benefits and harms,
this section features three questions requiring panelists
to judge the magnitude of desirable and undesirable ef-
fects, as well the relation between the two. Panelists
struggled judging the size of the benefits and harms con-
sistently. Two methodologists considered the three ques-
tions redundant and suggested to drop the questions
about the size of the benefit and harms and maintain
only the one addressing their balance.
Discussion
This is the first study evaluating the use of the GRADE
EtD framework in the context of real guideline develop-
ment. Given the widespread application of GRADE, this
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Table 3 Summary of the results
Section in the EtD table Compiled feedback
Order of columns and rows The order was not a relevant issue for most panels
Criteria in EtD One methodologist expressed concerns regarding the overlap between the sections
“acceptability” and “feasibility” with “values and preferences” and “resource considerations”.
Another methodologist considered the section “priority” redundant.
According to another methodologist, the criteria of the table were not easy to apply to
recommendations addressing multiple comparisons.
Judgment column Two methodologists stated that allowing modifications to the answer options might be
needed to accommodate different contexts and scenarios.
Research evidence Although for the majority of panels there were no issues with this column, one
methodologist stated that the difference between the purposes of the columns “available
evidence” and “additional consideration” was not clear.
Additional considerations One methodologist suggested using this column to summarize the available evidence as a
general narrative statement.
Background One methodologist considered this section redundant (with respect to information that is
present in the main text of the guideline).
PICO Three methodologists expressed concerns regarding how the question is presented,
specifically, they suggested making the PICO structure more explicit (and using the exact
terms that P-I-C-O stand for).
Perspective One methodologist considered this section particularly relevant, as being explicit about the
perspective may help to make transparent the decisions made to formulate
recommendations.
Overall certainty of the Evidence In general, this section was well evaluated by methodologists, with no major suggestion for
improvement. Two methodologists made minor wording suggestions.
Another methodologist suggested expanding the content to include more information
about each particular outcome.
Values and preferences (“Uncertainty about how much
people value the main outcomes”)
This section posed significant difficulties in several panels. Four methodologists suggested
differentiating between “variability” and “uncertainty” of patients’ values and preferences.
Another methodologist suggested making explicit the source of patients’ values and
preferences. The order of presenting and discussing values and preferences was also
questioned and subsequently changed in the EtD framework.
Balance of benefits and harms There were major difficulties in 6 guideline panels. According to methodologists, panelists
had problems answering consistently the questions about the size of the effect.
Additionally, two methodologists considered the questions of this section redundant.
Resource use Three guideline panels (all without health economists) struggled answering the question
about the relationship between incremental cost and benefits. These panels proposed “is
the treatment cost-effective?” as a better alternative. The only guideline panel with health
economists considered the questions of this section too superficial.
Equity Three guideline panels struggled with this question. A more clear definition of health equity
and more guidance on how to answer the question were considered necessary.
Two methodologists suggested adding the option “no effect on health equity” to the
answers options.
Acceptability Two methodologists expressed problems when trying to identify the relevant stakeholders.
More guidance was considered necessary.
Feasibility None
Panel decisions One methodologist considered the wording of this section confusing when the
recommendation under discussion involved two active treatments.
Another methodologist suggested de-emphasizing the option “no recommendation”
Justification/remarks Two panels struggled to decide what to include in the remarks. More guidance was
considered necessary.
Subgroup considerations One methodologist considered that subgroups should be more explicit in the table.
Implementation considerations According to methodologists, this section was used in different ways across guideline
panels. More guidance in what to include was considered necessary.
Monitoring and evaluation None
Research priorities In general, there was agreement regarding the importance of this section.
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study provides important information and rationale for
utilizing EtDs in guidelines. In general, the response to the
use of the EtD framework was positive, although some
sections (i.e., “values and preferences” and “balance be-
tween benefits and harms”) required improvements, in
particular the choice of answer options. These improve-
ments have been implemented in the current final option
of GRADE EtD frameworks (www.gradepro.org) [11–13].
There are some limitations to this study. The use of it-
eratively developed formats of the EtD framework in dif-
ferent guideline panels could have introduced some
variability in the provided answers. However, it was ne-
cessary as part of the development and improvement of
the EtDs. For example, early testing with the World
Health Organization and World Allergy Organization
panels revealed difficulties with providing responses to
the available answer options. In order to make best use
of the EtDs, they were modified for use in the work of
later guideline panels. While methodologists were pro-
spectively instructed before the panel meetings to record
challenges with the EtDs during the panel meetings,
there was no independent evaluation of challenges with
the EtD frameworks. However, the data were recorded
without delay and we believe that recall of the encoun-
tered issues does not lead to bias as all methodologists
had an interest in improving the frameworks.
The strengths of this study include the strategies taken
to ensure the trustworthiness of our findings: prospect-
ive data collection, independent and duplicate analysis,
and member checking of the conclusions. The most im-
portant strength of this work is the application of the
EtD frameworks in the context of real guideline develop-
ment by international panels in a broad range of topics,
including diagnostic and therapeutic questions.
Our findings strongly suggest that the EtD framework
can enhance the transparency of guideline developers’
judgments, allowing decision makers to truly assess the
recommendation. This is not only corroborated by this
work but by the adoption of the EtD approach by major
organizations such as WHO [21]. What happens within
guideline panels is seldom reported in current guidelines
[22–26]. Hence, when recommendations are analyzed at
a deeper level, some decisions of the panel might seem
arbitrary and unjustified. Providing details about the rea-
sons and judgments behind such decisions enrich the
recommendations and also may facilitate the adaptation
of international guidelines to local contexts. In the EtDs,
each criterion is considered by working trough the EtD
sequentially and then in a summary before formulating a
recommendation. This avoids unnecessarily moving back
and forth between criteria and wasting time. In addition,
each criterion requires a judgment that determines the
direction and strength of a recommendation, which is
often not found in guidelines. This information will
facilitate updating (by seeing judgments and evaluating
if the should change) and adaptation of guidelines (by
making others aware of the judgments).
The EtD framework also offers the opportunity to
identify and potentially avoid inappropriate recommen-
dations. One potential problem of recommendations is
the mismatch between the strength of the recommenda-
tion and the underlying information about the certainty
in effect estimates (also known as confidence in the evi-
dence or quality of the evidence), the balance between
the benefits and harms, values and preferences, and re-
source considerations [27]. The EtD framework, on the
one hand, allows users to judge to what extent the rec-
ommendation corresponds to the underlying informa-
tion and, on the other hand, may help preventing
guideline developers from inappropriately grading the
strength of the recommendation [28]. Finally, the EtD
framework may also be a valuable research tool, since it
would allow a detailed comparison of conflicting recom-
mendations from different organizations.
Conclusions
In conclusion, the use of an EtD framework in guide-
line development offers an explicit and transparent way
to record and report the judgments and discussion of
guideline panelists. The EtD framework may facilitate
the assessment of recommendations and also their po-
tential adaptation and implementation. As result of this
work, a new section was added to the EtD framework.
This section allows summarizing the judgments of
guideline panelists just prior to the deliberations re-
garding the direction and strength of recommenda-
tions. The currently latest version of the EtD resulting
from this and other work including an interactive
version of the EtD based on this and other work is
available in GRADE’s online GRADEpro Guideline De-
velopment Tool (www.gradepro.org) and described
elsewhere [11–13]. While the current formats of EtD
frameworks are already used widely, future use and re-
search will inform changes that will have to be made to
the EtDs. To name some areas of relevance, additional
research could identify how to best integrate issues
arising from potential conflicts of interest, how to
structure research recommendations, how to address
agreement of panel members with information pro-
vided by systematic reviews, how to document alter-
ations in judgments about the certainty in the evidence
by panel members as a result of indirectness of the evi-
dence [29], and how to structure implementation con-
siderations. The GRADE working group will further
evaluate and develop the EtD frameworks. Doing this,
the evaluation of the EtD frameworks in real guideline
development processes should continue to provide in-
formation for improvement.
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Framework example. (DOC 188 kb)
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Acknowledgements
We thank all panelists and methodologists of the guidelines in which this
EtD framework was tested.
Funding
This project has been funded by the European Union’s Seventh Framework
Programme for research, technological development and dissemination
under grant agreement no. 258583 (www.decide-collaboration.eu), the
Ministry of Health of the Kingdom of Saudi Arabia, and the McMaster GRADE
center.
Authors’ contribution
HJS, PAC and WW conceived of the study and participated in its design and
coordination. IN and RBP participated in its design and conducted the
analysis. ACL, CC, EA, RAM, WA, IEI, MXR, MF, NS, JB and AI provided
substantial contributions to the interpretation of the findings. IN and HJS
drafted the manuscript. PAC, WW, RBP, ACL, CC, EA, RAM, WA, IEI, MXR, MF,
NS, JB and AI revised the manuscript critically. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Clinical Epidemiology and Biostatistics, McMaster University,
Hamilton, Canada. 2Department of Internal Medicine, School of Medicine,
Pontificia Universidad Catolica de Chile, Santiago, Chile. 3Evidence-Based
Dentistry Unit, Faculty of Dentistry, University of Chile, Santiago, Chile.
4Department of Internal Medicine, American University of Beirut, Beirut,
Lebanon. 5Department of Medicine/Nephrology and Biomedical and Health
Informatics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
6Department of Clinical Epidemiology & Biostatistics, McMaster University
Health Sciences Centre, Room 2C16, 1280 Main Street West, Hamilton, ON
L8S 4K1, Canada. 7Basque Office for Health Technology
Assessment-OSTEBA—Directorate for Health Research and Innovation,
Ministry for Health Basque Government, Vitoria-Gasteiz, Spain. 8Department
of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Pontificia
Universidad Javeriana, Bogotá, Colombia. 9Institute for Education and
Research, Hospital Moinhos de Vento, Porto Alegre, Brazil. 10Iberoamerican
Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant
Pau-CIBERESP), Barcelona, Spain.
Received: 21 December 2015 Accepted: 20 June 2016
References
1. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines:
potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;
318(7182):527–30.
2. Eccles MP, Grimshaw JM, Shekelle P, Schunemann HJ, Woolf S. Developing
clinical practice guidelines: target audiences, identifying topics for
guidelines, guideline group composition and functioning and conflicts of
interest. Implemen Sci. 2012;7:60.
3. Shekelle P, Woolf S, Grimshaw JM, Schunemann HJ, Eccles MP. Developing
clinical practice guidelines: reviewing, reporting, and publishing guidelines;
updating guidelines; and the emerging issues of enhancing guideline
implementability and accounting for comorbid conditions in guideline
development. Implemen Sci. 2012;7:62.
4. Woolf S, Schunemann HJ, Eccles MP, Grimshaw JM, Shekelle P. Developing
clinical practice guidelines: types of evidence and outcomes; values and
economics, synthesis, grading, and presentation and deriving
recommendations. Implemen Sci. 2012;7:61.
5. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B,
Graham ID, Grimshaw J, Hanna SE, et al. AGREE II: advancing guideline
development, reporting and evaluation in health care. J Clin Epidemiol.
2010;63(12):1308–11.
6. Institute of Medicine (US) Committee on Standards for Developing
Trustworthy Clinical Practice Guidelines; Editors: Robin Graham, Michelle
Mancher, Dianne Miller Wolman, Sheldon Greenfield, and Earl Steinberg.
Washington (DC): National Academies Press (US); 2011 (available at: http://
www.nap.edu/openbook.php?record_id=13058)
7. Schunemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N,
Mustafa R, Ventresca M, Brignardello-Petersen R, Laisaar KT, Kowalski S, et al.
Guidelines 2.0: systematic development of a comprehensive checklist for a
successful guideline enterprise. CMAJ. 2014;186(3):E123–142.
8. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH,
Harbour RT, Haugh MC, Henry D, et al. Grading quality of evidence and
strength of recommendations. BMJ. 2004;328(7454):1490.
9. Schünemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and
words: how to communicate grades of evidence and recommendations.
CMAJ. 2003;169(7):677–80.
10. Treweek S, Oxman AD, Alderson P, Bossuyt PM, Brandt L, Brozek J, Davoli M,
Flottorp S, Harbour R, Hill S, et al. Developing and Evaluating Communication
Strategies to Support Informed Decisions and Practice Based on Evidence
(DECIDE): protocol and preliminary results. Implement Sci. 2013;8:6.
11. Schunemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G,
Scholten R, Langendam M, Leeflang MM, Akl EA, et al. GRADE Guidelines:
16. Development of the GRADE Evidence to Decision (EtD) frameworks
for tests in clinical practice and public health. J Clin Epidemiol 2016.
doi: 10.1016/j.jclinepi.2016.01.032.
12. Alonso-Coello P, Schunemann H, Moberg J, Brignardello-Petersen R, Akl E,
Davoli M, Treweek S, Mustafa R, Rada G, Rosenbaum S, Morelli A, Guyatt GH,
Oxman AD. GRADE Evidence to Decision frameworks: 1. Introduction.
BMJ in press.
13. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl E, Davoli
M, Treweek S, Mustafa R, Vandvik, P, Meerpohl, J, Guyatt, GH, Schunemann H.
GRADE Evidence to Decision frameworks: 2. Clinical practice guidelines.
BMJ in press.
14. World Health Organization. The use of bedaquiline in the treatment of
multidrug-resistant tuberculosis. Interim policy guidance http://apps.who.
int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf. Accessed
8 Dec 2014. In.; 2013.
15. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG,
Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, et al. WHO Rapid
Advice Guidelines for pharmacological management of sporadic human
infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7(1):21–31.
16. Schunemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, Wisloff TF,
Del Mar C, Hayden F, Uyeki TM, et al. Transparent development of the WHO
rapid advice guidelines. PLoS Med. 2007;4(5):e119.
17. Santesso N, Schunemann H, Blumenthal P, De Vuyst H, Gage J, Garcia F,
Jeronimo J, Lu R, Luciani S, Quek SC, et al. World Health Organization
Guidelines: use of cryotherapy for cervical intraepithelial neoplasia.
Int J Gynaecol Obstet. 2012;118(2):97–102.
18. Saudi Arabian Clinical Practice Guideline on Allergic Rhinits in Asthma
(available at: http://www.moh.gov.sa/endepts/Proofs/Pages/Guidelines.aspx)
19. Schünemann HJ, Brozek J. GRADEpro Guideline Development Tool. In.
Hamilton, Canada: McMaster University; 2015.
20. Schünemann H, Wiecioch W, Brozek J, Etxeandia-Ikobaltzetaen I, Mustafa R,
Manja V, Brignadello-Peterson R, Neumann I, Falavigna M, Al-Hazzani W,
et al. GRADE Evidence to Decision Frameworks for adoption, adaptation
and de novo development of trustworthy recommendations: GRADE-
ADOLOPMENT J Clin Epidemiol 2016, accepted for publication.
21. WHO handbook for guideline development. Geneva, Switzerland: World
Health Organization; 2014.
22. Alonso-Coello P, Irfan A, Sola I, Gich I, Delgado-Noguera M, Rigau D, Tort S,
Bonfill X, Burgers J, Schunemann H. The quality of clinical practice
guidelines over the last two decades: a systematic review of guideline
appraisal studies. Qual Saf Health Care. 2010;19(6):e58.
23. Raine R, Sanderson C, Black N. Developing clinical guidelines: a challenge to
current methods. BMJ. 2005;331(7517):631–3.
24. Oxman AD, Fretheim A, Schunemann HJ. Improving the use of research evidence
in guideline development: introduction. Health Res Policy Syst. 2006;4:12.
25. Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 14. Reporting guidelines. Health Res
Policy Syst. 2006;4:26.
Neumann et al. Implementation Science  (2016) 11:93 Page 7 of 8
26. Wilson KC, Irwin RS, File Jr TM, Schunemann HJ, Guyatt GH, Rabe KF.
Reporting and publishing guidelines: article 12 in Integrating and
coordinating efforts in COPD guideline development. An official ATS/ERS
workshop report. Proc Am Thorac Soc. 2012;9(5):293–7.
27. Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P,
Agoritsas T, Mustafa RA, Alexander PE, Schunemann H, et al. A guide for
health professionals to interpret and use recommendations in guidelines
developed with the GRADE approach. J Clin Epidemiol.
2016;72:45–55.
28. Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B,
Stoltzfus R, Montori VM, Norris SL, Schunemann HJ, et al. World Health
Organization strong recommendations based on low-quality evidence
(study quality) are frequent and often inconsistent with GRADE guidance.
J Clin Epidemiol. 2016;72:98–106.
29. Schunemann HJ. Interpreting GRADE's levels of certainty or quality of the
evidence: GRADE for statisticians, considering review information size or less
emphasis on imprecision? J Clin Epidemiol. 2016;75:6–15.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Neumann et al. Implementation Science  (2016) 11:93 Page 8 of 8
